Bio-Techne (TECH) said it plans to seek shareholder approval at its upcoming 2022 annual meeting to implement a four-for-one stock split in the form of a stock dividend.Following…
→ Google 번역
MINNEAPOLIS , Sept. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced its plan to request shareholder approval during its upcoming 2022 Annual Meeting of Shareholders (the "Annual Meeting") for an increase in the total number of authorized shares of common stock through an amendment to the Company''s Articles of Incorporation to implement a four-for-one forward stock split in the form of a stock dividend. The proposed amendment to the Company''s Articles of Incorporation will be voted on by shareholders during Bio-Techne''s Annual Meeting on October 27, 2022 . Following shareholder approval, Bio-Techne''s Board of Directors intends to declare the stock split and set a record date and distribution date for the stock dividend. The stock dividend is expected to occur in the Company''s second quarter of fiscal 2023. Additional details regarding Bio-Techne''s Annual Meeting, as well as the proposed four-for-one stock split can be found in the preliminary proxy that was filed with the Securities and Exchange Commission (SEC) on September 1, 2022 , and the definitive proxy statement which is expected to be filed with the SEC on or about Full story available on Benzinga.
→ Google 번역
MINNEAPOLIS , Aug. 24, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that it has been included in the Forbes list of Best-in-State Employers 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list can currently be viewed on the Forbes website. America''s Best-in-State Employers 2022 were identified in an independent survey based on a vast number of participants of approximately 70,000 … Full story available on Benzinga.com
→ Google 번역
New products posted to GenomeWeb for the week of Aug. 15, 2022.
→ Google 번역
Bio-Techne Corporation (NASDAQ:NASDAQ:TECH) Q4 2022 Earnings Conference Call August 4, 2022 9:00 am ET Corporate Participants David Clair - Vice President, Investor Relations and Corporate…
→ Google 번역
https://www.investing.com/news/pro/biotechne-corp-pt-lowered-to-501-at-craighallum-432SI-2865336
→ Google 번역
https://www.investing.com/news/pro/biotechne-corp-pt-lowered-to-500-at-stifel-432SI-2864020
→ Google 번역
Bio-Techne (NASDAQ:TECH) declares $0.32/share quarterly dividend, in line with previous.Forward yield 0.33%Payable Aug. 29; for shareholders of record Aug. 15; ex-div Aug.
→ Google 번역
Bio-Techne press release (TECH): Q4 Non-GAAP EPS of $2.05 misses by $0.03.Revenue of $288.2M (+11.3% Y/Y) beats by $1.16M.
→ Google 번역
Bio-Techne (TECH) is scheduled to announce Q4 earnings results on Thursday, August 4th, before market open.The consensus EPS Estimate is $2.08 (+11.2% Y/Y) and the consensus…
→ Google 번역
Bio-Techne is a long-term cash compounder that offers a layer of resiliency into investor portfolios.
→ Google 번역
When the equities sector started to unravel as soaring inflation and the conflict in eastern Europe took its toll on investor sentiment, the technology sector was one of the hardest hit. Since these enterprises are largely geared toward maximizing growth, when opportunities for economic expansion are limited, the segment tends to suffer. However, the bearishness may have gone overboard, thus bolstering tech stocks trading at a discount. One main reason to consider picking up deflated shares is that innovation always moves forward. With digitalization becoming an even more ingrained reality than in the past, it’s a likely bet that tech stocks focused on wider connectivity will eventually recover. However, investors can enjoy the greatest rewards by getting in early before the wave. 5 Best Stocks to Buy if You Have $100 to Spend Second, some platforms are so deeply integrated into society that they’ve essentially become indispensable. As well, broader labor force developments such as the gig economy will likely ensure that tech stocks — despite their current volatility — maintain their relevance.
→ Google 번역
Bio-Techne (TECH) said it launched the CE-IVD marked RNAscope ISH Probe High Risk HPV test in Europe for use in throat cancer.The test is intended for use in patients diagnosed…
→ Google 번역
Bio-Techne (TECH) is acquiring Mountain View, Calif.-based Namocell.Financial terms of the deal were not disclosed the company''s June 22 press release.Namocell provides single cell…
→ Google 번역
FinancialNewsMedia.com News Commentary PALM BEACH, FL , June 21, 2022 /PRNewswire/ -- Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly in the case of cancer or heart conditions. This reality is encouraging more companies to seek treatments for recurring conditions. Here we discuss companies treating recurring health conditions in reference to Merck (NYSE: MRK ), Bio-Techne Corporation (NASDAQ: TECH ), Natera (NASDAQ: NTRA ) and Cardiol Therapeutics (NASDAQ: CRDL ) (TSX: CRDL ). Triple-negative breast cancer is the most aggressive type of breast cancer, with the highest risk of recurrence within the first five years after diagnosis. Merck (NYSE: MRK ) just had its drug KEYTRUDA® (pembrolizumab) plus chemotherapy approved by the European Commission to treat locally advanced or early-stage triple-negative breast cancer at high risk of recurrence. This offers enormous encouragement to those suffering from this devastating condition.
→ Google 번역
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
→ Google 번역
Aristotle Capital Management, an independent/employee-owned investment management organization, published its “Aristotle Core Equity” first quarter 2022 investor letter – a copy of which can be …
→ Google 번역
Soaring Stocks Break 100-Year-Record Losing-Streak Amid Macro Meltdown US Macro data has disappointed for 6 straight weeks with May set to see the biggest plunge in reported data relative to expectations since the collapse in April 2020 when the economy was effectively shuttered down by the government… Source: Bloomberg But it appears that bad news is good news once again (with ugly data, FedSpeak, and the Minutes all being interpreted as 2x 50bps hikes then pause in Sept... which just seems too easy) as after seven (or eight for The Dow) straight weeks lower for the Nasdaq and S&P, this week saw stocks ''dead cat bounce'', soaring higher led by Nasdaq (the worst performer on the downside swing). Nasdaq is up 10% off last Friday''s lows, Small Caps and S&P +9% and Dow +8%... Just look at today''s moves, Nasdaq +3%, S&P up over 2% all triggered at 0830ET when Core PCE came in as expected (and headline PCE was hotter than expected?!) and then extended gains on the terrible UMich print with inflation expectations hovering at 40 year highs...
→ Google 번역
Investors are turning to defensive growth stocks that boast dominant positions in their respective markets. Adobe ( ADBE ): Leading productivity and design solutions for the digital media market with growing enterprise demand. Fiserv ( FISV ): Management anticipates 7% to 9% organic revenue growth and adjusted earnings per share growth of 15% to 17%. IBM ( IBM ): Guided for at least $10 billion of free-cash-flow generation and supports a generous 4.9% dividend yield. Intel ( INTC ): Strong data center and networking markets are expected to offset the downturn in PC demand. Intuitive Surgical ( ISRG ): Commands almost 80% of the global market in robotic-assisted surgeries. T-Mobile ( TMUS ): Reported industry-leading growth in postpaid and broadband customers. Vanguard Small-Cap Growth Index Fund ETF Shares ( VBK ): Offers exposure to a diversified group of small growth companies. Source: wan wei / Shutterstock.com Interest rate hikes and soaring inflation are making investors look for defensive growth stocks.
→ Google 번역
Bio-Techne Corporation (NASDAQ:NASDAQ:TECH) Q3 2022 Earnings Conference Call May 04, 2022 09:00 AM ET Company Participants David Clair - Senior Director, IR and Corporate Development Chuck…
→ Google 번역
Bio-Techne (NASDAQ:TECH) declares $0.32/share quarterly dividend, in line with previous.Forward yield 0.33%Payable May 27; for shareholders of record May 16; ex-div May 13.See TECH Dividend…
→ Google 번역
Bio-Techne press release (TECH): Q1 Non-GAAP EPS of $2.14 beats by $0.14.Revenue of $290.4M (+19.2% Y/Y) beats by $11.13M.
→ Google 번역
(PLX AI) – Bio-Techne Q3 EPS USD 1.48.Q3 revenue USD 290.4 million vs. estimate USD 279 million
→ Google 번역
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) (announced a collaboration with Biovac to manufacture COVID-19 shots in South Africa) Bristol-Myers Squibb Company (NYSE: BMY ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Century Therapeutics, Inc. (NASDAQ: IPSC ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced positive data for pipeline asset in periodontal disease) Eli Lilly and Company (NYSE: LLY ) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) (reacted to its second-quarter results) Novo Nordisk A/S (NYSE: NVO ) PLx Pharma Inc. (NASDAQ: PLXP ) ResMed Inc. (NYSE: RMD ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) 23andMe Holding Co.
→ Google 번역
Based on the historical situation of the past five years (2016-2020),GLOBAL INFO RESEARCH analyzes the overall scale of global Calpain in the past few years, the scale of major regions, the scale and share of major enterprises, the scale of major product classifications, and the scale of major downstream applications. Scale analysis includes sales volume, price, revenue, []
→ Google 번역
Based on the historical situation of the past five years (2016-2020),GLOBAL INFO RESEARCH analyzes the overall scale of global Receptor Tyrosine Kinase in the past few years, the scale of major regions, the scale and share of major enterprises, the scale of major product classifications, and the scale of major downstream applications. Scale analysis includes sales volume, []
→ Google 번역
This report studies the Freezing Culture Media Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Freezing Culture Media market segmented by company, []
→ Google 번역
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced new preclinical data for its lead drug candidate atuzaginstat in periodontal disease) Intuitive Surgical, Inc. (NASDAQ: ISRG ) (reacted to better-than-expected second-quarter results) Forward Pharma A/S (NASDAQ: FWP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 21) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Cyteir Therapeutics, Inc. (NASDAQ: CYT ) Elevation Oncology, Inc. (NASDAQ: ELEV ) Ensysce Biosciences, Inc. (NASDAQ: ENSC ) ERYTECH Pharma S.A. (NASDAQ: ERYP ) HCW Biologics Inc. (NASDAQ: HCWB ) (IPOed Tuesday) Lumos Pharma, Inc. (NASDAQ: LUMO ) ( signaled a delay in clinical trials of its treatment for pediatric growth deficiency) Medicenna Therapeutics Corp. (NASDAQ: MDNA ) Nautilus Biotechnology, Inc. (NASDAQ: NAUT ) OptiNose, Inc. (NASDAQ: OPTN ) POINT Biopharma Global Inc. (NASDAQ: PNT ) Regencell Bioscience Holdings Limited (NASDAQ: RGC ) (IPOed Friday) VectivBio Holding AG (NASDAQ: VECT ) Yumanity Therapeutics, Inc. (NASDAQ: YMTX ) Stocks In Focus Erytech Plans Regulatory Submission For Eryaspase In Blood Cancer Following Positive Pre-BLA Meeting Erytech said it intends to move forward toward the submission of a biologic license application to the U.S.
→ Google 번역
Regarding the trend, note that the strongest trend exists on the 100 day timeframe. The post BIO-TECHNE Corp (TECH): Price Now Near $459.52; Daily Chart Shows An Uptrend on 20 Day Basis appeared first on ETF Daily News .
→ Google 번역
Top Players Covered in the Host Cell Contaminant Testing Market Research Report Cisbio Bioassays, Cygnus Technologies, Bio-Rad Laboratories Inc., Enzo Life Sciences Inc., BioGenes, Molecular Devices LLC., ForteBio, GENERAL ELECTRIC COMPANY, Thermo Fisher Scientific, ProteinSimple., Bio-Techne, BioAgilytix Labs Are and other key market players. Top Players Covered in the Host Cell Contaminant Testing Market Research Report Cisbio Bioassays, Cygnus Technologies, Bio-Rad Laboratories Inc., Enzo Life Sciences Inc., BioGenes, Molecular Devices LLC., ForteBio, GENERAL ELECTRIC COMPANY, Thermo Fisher Scientific, ProteinSimple., Bio-Techne, BioAgilytix Labs Are and other key market players.
→ Google 번역
The industry research report Global Human FGFR3(Fibroblast growth factor receptor) Market 2021 consists of an in-depth analysis of the global industry that aims to offer a comprehensive study of market insights associated with the most important components of the market. The report gives an outline of these business sectors on different fronts, for example, market size, portion []
→ Google 번역
Bio-Techne Corp (TECH) shares closed today at 1.9% below its 52 week high of $467.63, giving the company a market cap of $17B. The stock is currently up 44.7% year-to-date, up 64.6% over the past 12 months, and up 329.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 39.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 278.7% The company's stock price performance over the past 12 months beats the peer average by 128.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 195.8% higher than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google 번역
Cell and Gene Therapy Manufacturing QC Market research report is the new statistical data source added by A2Z Market Research. It uses several approaches for analyzing the data of target market such as primary and secondary research methodologies. It includes investigations based on historical records, current statistics, and futuristic developments. The report gives a []
→ Google 번역
Bio-Techne Corp (TECH) shares closed today at 1.9% below its 52 week high of $467.63, giving the company a market cap of $17B. The stock is currently up 44.7% year-to-date, up 68.9% over the past 12 months, and up 329.8% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 0.9%. Trading Activity Trading volume this week was 49.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 1.6% higher than its 5-day moving average, 2.1% higher than its 20-day moving average, and 9.8% higher than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 278.7% The company's stock price performance over the past 12 months beats the peer average by 124.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 195.8% higher than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google 번역
Bio-Techne Corp (TECH) shares closed today at 1.9% below its 52 week high of $467.63, giving the company a market cap of $17B. The stock is currently up 44.7% year-to-date, up 68.9% over the past 12 months, and up 329.8% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 0.9%. Trading Activity Trading volume this week was 49.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 1.6% higher than its 5-day moving average, 2.1% higher than its 20-day moving average, and 9.8% higher than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 278.7% The company's stock price performance over the past 12 months beats the peer average by 124.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 195.8% higher than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google 번역
Related Stocks: TECH ,
→ Google 번역
Acute Myeloid Leukemia is a cancer of myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid build-up of abnormal white blood cells causes interference in the production of normal blood
→ Google 번역
Major players in the fetal bovine serum market are Sartorius AG, GE Healthcare, PAN- Biotech, Thermo Fisher Scientific Inc. , Biowest, Bio-Techne, Rocky Mountain Biologicals Inc. , Merck KGaA, TCS Biosciences Ltd, Bovogen Biologicals Pty Ltd, Tissue Culture Biologicals, Atlanta Biologicals Inc. Major players in the fetal bovine serum market are Sartorius AG, GE Healthcare, PAN- Biotech, Thermo Fisher Scientific Inc. , Biowest, Bio-Techne, Rocky Mountain Biologicals Inc. , Merck KGaA, TCS Biosciences Ltd, Bovogen Biologicals Pty Ltd, Tissue Culture Biologicals, Atlanta Biologicals Inc.
→ Google 번역
Compounding Returns In a world obsessed with price movements of stocks, its easy to lose sight of what those prices represent the value of holding a companys future profit potential. One of the key ways that profit potential turns into profit actualization in an investors pocket is the dividend cash (usually) payments made Read More » Why Worry With Dividends? Their Five-Year Reinvested Value for Bio-Techne The post Why Worry With Dividends? Their Five-Year Reinvested Value for Bio-Techne appeared on Stocks News Feed .
→ Google 번역
Compounding Returns In a world obsessed with price movements of stocks, its easy to lose sight of what those prices represent the value of holding a companys future profit potential. One of the key ways that profit potential turns into profit actualization in an investors pocket is the dividend cash (usually) payments made Read More »Why Worry With Dividends? Their Five-Year Reinvested Value for Bio-Techne
→ Google 번역
Laguna-based Cirtek Holdings Philippines Corp. on Thursday said it continues to collaborate with its customers to address the
→ Google 번역
Laguna-based Cirtek Holdings Philippines Corp. on Wednesday said it secured the approval of the Philippine Stock Exchange Inc.
→ Google 번역
Bio-Techne Corporation announced that they will be opening a new facility located in Dublin, reflecting their commitment to expanding into Europe. Bio-Technes Dublin Facility Bio-Techne is a Minneapolis-based, NASDAQ-listed Life Science, Clinical Diagnostic as well as Bioprocessing company. The Dublin facility will be responsible for servicing the companys growing number of European-based academic and biopharma []
→ Google 번역
Bio-Techne has opened a new facility in Dublin, Ireland, to support the life sciences industry in Europe and to meet expectations in growth.
→ Google 번역
Coherent Market Insights has announced the addition of the Global Mesenchymal Stem Cells Market Size, Status and Forecast 2027, The report classifies the market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well
→ Google 번역
How to Buy Bio-Techne (TECH) Stock Right Now Benzinga Benzinga
→ Google 번역
Pixion Market Research Latest 2021 Report : The Global Mesenchymal Stem Cells Market Research Report represents a comprehensive study on the Mesenchymal Stem Cells industry including current trends and status. At an initial stage, the Mesenchymal Stem Cells market report offers basic information including definitions, classifications, a wide range of applications, and the Mesenchymal Stem []
→ Google 번역
IVD Quality Control Market ( EMAILWIRE.COM , June 18, 2021 ) According to research report the global IVD Quality Control Market is projected to reach $1,158 million by 2025 from $961 million in 2020, at a CAGR of 3.8% during the forecast period. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582 Some of the factors driving the growth of the In Vitro Diagnostics Quality Control Market are increasing number of accredited clinical laboratories, rising demand for external quality assurance support, and growing adoption of third-party quality controls. The prominent players in this IVD Quality Control Market are Bio-Rad Laboratories Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific Inc. (US), Technopath Clinical Diagnostics (Ireland), Bio-Techne Corporation (US), Fortress Diagnostics (UK), SeraCare Life Sciences Inc. (US), SERO AS (Norway), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), and Abbott Laboratories Inc. (US).
→ Google 번역
Bio-Techne (NASDAQ: TECH), J2 Global (NASDAQ: JCOM) and InMode (NASDAQ: INMD) recently passed buy points, a signal that institutional buyers have conf
→ Google 번역
As per the research conducted by MarketsandResearch.biz, the report titled Global Indiplon Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 includes a lot of details that allow everyone to understand different things without difficulties. In the introductory part of the chapter, details about global Indiplon market figures, both historical and estimates are []
→ Google 번역